News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results


8/12/2014 8:25:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014.

“Top-line results are expected in early October from our Phase 2b ETC-1002-008 clinical trial in statin intolerant patients. Results from our 2-year carcinogenicity studies are anticipated late in the fourth quarter, while top-line results from two additional Phase 2 studies are expected in the first half of 2015,” said Tim M. Mayleben, president and chief executive officer of Esperion. “We believe that ETC-1002 is the right drug in development for the treatment of patients with hypercholesterolemia and a history of statin intolerance. This is a patient population that is increasingly recognized as deserving of more effective oral therapy options.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES